Preclinical CRO for metabolic diseases and complications - Physiogenex About Company overview Management Team Scientific Advisory Board Partners Consultancy Research Services Insulin resistance - Diabetes Dyslipidemia - Atherosclerosis NASH - Fibrosis Obesity Nutraceuticals Preclinical imaging Quality Commitments Facilities Innovation Publications News Contact us The scientific focus adapted to express the optimum potential of your molecule Marketing: Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning. HeartArteryMacrophageLiverMusclePancreasAdipose Tissue Preclinical development: In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs. Discovery: Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision. Home Physiogenex is a preclinical research organization that offers outstanding consultancy and research services, specializing in metabolic disorders such as diabetes, obesity, liver diseases (NASH), dyslipidemia, atherosclerosis and cardiovascular complications. More than just a CRO, we are your R&D partner of choice to target your specific needs. Our models and technologies are customized and we deliver unparalleled scientific expertise for R&D, preclinical development, post-marketing studies and drug repositioning. We also offer in vivo preclinical imaging services. We provide both the biopharmaceutical and nutraceutical companies with optimal and reliable solutions for successful strategic decision-making. R&D, Preclinical and Post marketing studies DIABETES Insulin resistance OBESITY LIVER DISEASES NAFLD Hepatic steatosis to fibrosis DYSLIPIDEMIA ATHEROSCLEROSIS DIABETIC NEPHROPATHY Animal models from basic to predictive in-house models Experimental platform From gold-standard to innovative assays Scientific expertise and translational vision News, Events and Publications Physiogenex introduces innovative imaging techniques and LDL-kinetics to demonstrate your drug benefits on atherosclerosis Probiotic B420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice EASD 2015: Physiogenex presents a new hamster study evaluating the effects of SGLT2 inhibition on cholesterol metabolism Subscribe to our scientific publications and webinars Top Site mapLegal Mentions RSSLinkedInViadeoTwitterGoogle+ Member of